Kyto Technology And Life Science Inc Quick Ratio (KBPH) starting from the third quarter 2021 to third quarter 2020, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Kyto Technology And Life Science Inc   (KBPH)

Kyto Technology And Life Science Inc 's Quick Ratio

KBPH's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Kyto Technology And Life Science Inc 's Cash & cash equivalent grew by 92.39 % in the Q3 2021 sequentially, while Current Liabilities decreased, this led to improvement in Kyto Technology And Life Science Inc 's Quick Ratio to 9.55, above Kyto Technology And Life Science Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 222 other companies have achieved higher Quick Ratio than Kyto Technology And Life Science Inc in third quarter 2021. While Quick Ratio total ranking has improved so far during the Q3 2021 to 1039, from total ranking in the second quarter 2021 at 1841.

Explain Quick Ratio?
How much Cash & cash equivalents KBPH´s has?
What are KBPH´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

KBPH Quick Ratio (Dec 31 2021)
Q3		 (Sep 30 2021)
Q2		 (Jun 30 2021)
Q1		 (Mar 31 2021)
Q4		 (Dec 31 2020)
Q3
Y / Y Current Liabilities Change -23.35 % 67.33 % 394.59 % 4373.52 % 20.96 %
Y / Y Cash & cash equivalent Change 7.88 % -20.46 % 281.15 % 4159.59 % 34.65 %
Quick Ratio MRQ 9.55 3.74 2.63 1 6.78
KBPH's Total Ranking # 1039 # 1841 # 2186 # 3232 # 1217
Seq. Current Liabilities Change -24.62 % -53.83 % -87.26 % 1628.04 % 64.55 %
Seq. Cash & cash equivalent Change 92.39 % -34.35 % -66.51 % 155.03 % 41.86 %



Quick Ratio third quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 223
Healthcare Sector # 359
Overall Market # 1011


Quick Ratio Statistics
High Average Low
13.83 4.96 0.97
(Jun 30 2018)   (Dec 31 2018)




Financial Statements
Kyto Technology And Life Science Inc 's Current Liabilities $ 0 Millions Visit KBPH's Balance sheet
Kyto Technology And Life Science Inc 's Cash & cash equivalent $ 1 Millions Visit KBPH's Balance sheet
Source of KBPH's Sales Visit KBPH's Sales by Geography


Cumulative Kyto Technology And Life Science Inc 's Quick Ratio

KBPH's Quick Ratio for the trailling 12 Months

KBPH Quick Ratio

 (Dec 31 2021)
12 Months		 (Sep 30 2021)
12 Months		 (Jun 30 2021)
12 Months		 (Mar 31 2021)
12 Months		 (Dec 31 2020)
12 Months
Y / Y Current Liabilities TTM Growth 771.83 % 848.81 % 759.96 % 659.98 % -2.69 %
Y / Y Cash & cash equivalent TTM Growth 153.6 % 186.75 % 252.49 % 148.52 % 4.21 %
Quick Ratio TTM 1.61 1.57 1.64 1.57 5.53
Total Ranking TTM # 5661 # 5618 # 1947 # 1405 # 1939
Seq. Current Liabilities TTM Growth -1.09 % 1.94 % 9.09 % 692.6 % 7.65 %
Seq. Cash & cash equivalent TTM Growth 1.59 % -2.82 % 14.06 % 125.22 % 14.86 %

Quick ratio ranking by company, industry and sector >> Back to KBPH Financial Strength Comparisons >> Go to Compare KBPH Quick Ratio to its Competitors

On the trailing twelve months basis KBPH Cash & cash equivalent improved by 7.88 % in Q3 2021 year on year, while Current Liabilities faded to $0 millions, this led to increase in in Kyto Technology And Life Science Inc 's Quick Ratio to 1.61, Quick Ratio remained below KBPH average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 598 other companies have achieved higher Quick Ratio than Kyto Technology And Life Science Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2021 from 5618 to 5661.

Explain Quick Ratio?
How much Cash & cash equivalents KBPH´s has?
What are KBPH´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 599
Healthcare Sector # 1191
Within the Market # 5661


trailing twelve months Quick Ratio Statistics
High Average Low
5.53 3.43 0.23
(Dec 31 2020)   (Dec 31 2018)




Companies with similar Quick Ratio in the quarter ending Dec 31 2021, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2021 MRQ Cash & cash equivalentDec 31 2021 MRQ Current Liabilities
Astria Therapeutics Inc   25.94 $ 125.508  Millions$ 4.838  Millions
Dogwood Therapeutics inc   25.84 $ 29.795  Millions$ 1.153  Millions
Kura Oncology Inc   25.65 $ 517.960  Millions$ 20.192  Millions
Lianbio  25.39 $ 383.249  Millions$ 15.092  Millions
Merrimack Pharmaceuticals Inc  25.27 $ 14.203  Millions$ 0.562  Millions
Cyteir Therapeutics Inc   25.26 $ 189.723  Millions$ 7.511  Millions
Kronos Bio Inc   24.92 $ 339.509  Millions$ 13.626  Millions
Bio path Holdings inc   24.82 $ 23.774  Millions$ 0.958  Millions
Prometheus Biosciences Inc   24.76 $ 257.254  Millions$ 10.392  Millions
Vistagen Therapeutics Inc   24.61 $ 103.108  Millions$ 4.189  Millions
Karuna Therapeutics Inc   24.44 $ 493.991  Millions$ 20.213  Millions
Genprex Inc   24.37 $ 38.629  Millions$ 1.585  Millions
Centessa Pharmaceuticals Plc  24.15 $ 595.082  Millions$ 24.638  Millions
Forte Biosciences Inc   23.92 $ 42.044  Millions$ 1.758  Millions
Onkure Therapeutics Inc   23.81 $ 147.670  Millions$ 6.202  Millions
Altimmune inc   23.42 $ 190.301  Millions$ 8.124  Millions
Morphic Holding inc   23.14 $ 408.135  Millions$ 17.636  Millions
Viking Therapeutics Inc   23.10 $ 202.103  Millions$ 8.749  Millions
Cerevel Therapeutics Holdings Inc   23.03 $ 565.688  Millions$ 24.562  Millions
Grace Therapeutics Inc  22.95 $ 48.195  Millions$ 2.100  Millions
Climb Bio Inc   22.63 $ 136.480  Millions$ 6.031  Millions
Sunshine Biopharma Inc   22.50 $ 2.053  Millions$ 0.091  Millions
Damora Therapeutics Inc   22.05 $ 100.191  Millions$ 4.544  Millions
Fulcrum Therapeutics Inc   21.89 $ 218.162  Millions$ 9.968  Millions
Oragenics Inc   21.79 $ 27.266  Millions$ 1.251  Millions
Minerva Neurosciences Inc   21.55 $ 60.755  Millions$ 2.819  Millions
Decibel Therapeutics Inc   21.42 $ 148.747  Millions$ 6.944  Millions
Pmv Pharmaceuticals Inc   21.42 $ 297.163  Millions$ 13.873  Millions
Lixte Biotechnology Holdings Inc   21.35 $ 4.824  Millions$ 0.226  Millions
Syndax Pharmaceuticals Inc   21.27 $ 439.936  Millions$ 20.683  Millions

Date modified: 2022-03-01T22:51:15+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.